Clinical trials: Demyelinating Disorder
Multiple Sclerosis (MS), Periodontal Diseases
Prevalence of Periodontitis in Egyptian Multiple Sclerosis Patients.
The goal of this observational study is to explore the association between multiple sclerosis and periodontal disease in a sample of Egyptian population The main question it aims to answer is: Is there an association between MS…
- Trial name
- NCT07195110
- Where
- Egypt
- Volunteers
- 293 people
- Sponsor
- Cairo University
Multiple Sclerosis, Upper Extremity Problem
Upper Extremity Motor Imagery Functional Skills and Quality of Life in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory and autoimmune disease of the central nervous system (CNS) characterised by axonal loss and demyelination. MS is characterized by myelin, oligodendrocyte and axon damage.
- Conditions
- Multiple Sclerosis, Upper Extremity Problem, Quality of Life, Image, Body
- Trial name
- MotorImagery (NCT06572059)
- Testing
- assesments for once
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Multiple Sclerosis, EDSS 4-7
Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis
The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment
- Trial name
- NCT01720849
- Testing
- Fampyra
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Vestre Viken Hospital Trust
Multiple Sclerosis
Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis
Multiple sclerosis, chronic inflammatory disease of the central nervous system, affects approximately 100,000 peoples in France. It is the leading cause of disability in young adults.
- Trial name
- GK-SEP (NCT03339908)
- Testing
- Thalamotomy by gamma Knife radiosurgery
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Multiple Sclerosis
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population
This study intends to explore the levels of MSRV expression by analyzing the levels of MSRV transcripts in blood, as well as the levels of the MSRV-Env protein in serum in the normal population.
- Trial name
- CONTROL (NCT01804660)
- Testing
- No study treatments administered
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis, Relapsing-Remitting
Rehabilitation Study in MS Patients
Studying the effectiveness of a functional rehabilitation protocol (FRP) in early Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with Betaferon by comparing the physical ability of patients with and without FRP.
- Trial name
- NCT00780455
- Testing
- Interferon beta-1b, FRP within 15 days after randomization, Interferon beta-1b, FRP about 6 weeks after randomization
- Where
- 10 sites in France
- Volunteers
- 4 people
- Sponsor
- Bayer
Secondary Progressive Multiple Sclerosis
A Study for Patients With Multiple Sclerosis
To obtain additional safety data in subjects who have previously completed the MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Multiple…
- Trial name
- MAESTRO-02 (NCT00870155)
- Testing
- dirucotide
- Where
- 10 sites in Canada, Denmark and 8 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis, Chronic Pain
MS Symptom Management Study
People with Multiple Sclerosis (MS) often have pain and/or fatigue. Unfortunately, available treatments provide inadequate relief for the majority of these individuals.
- Conditions
- Multiple Sclerosis, Chronic Pain, Fatigue
- Trial name
- ENHANCE (NCT02474940)
- Testing
- Intervention #1, Intervention #2, Intervention #3
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Washington
Multiple Sclerosis
Validation of the French Adaptation of the MSWDQ-23 Questionnaire
MS is an autoimmune disease of the central nervous system that affects more than 120,000 people in France. The average age of onset of the disease is between 25 and 35 years.
- Trial name
- WORKSEP (NCT04860791)
- Testing
- questionnaires
- Where
- 16 sites in France
- Volunteers
- 206 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
MEsenchymal StEm Cells for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), which ultimately leads to myelin damage and axonal loss.
- Trial name
- MESEMS (NCT02403947)
- Testing
- Mesenchymal stem cells, Suspension media
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Toulouse
Multiple Sclerosis, Relapsing-Remitting
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) affecting roughly 900,000 people in the United States that frequently results in impaired mobility.
- Trial name
- NCT04073940
- Testing
- Targeted Ballet Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Illinois at Urbana-Champaign
Multiple Sclerosis
Feasibility of a High-intensity Interval Training Program in Persons With Multiple Sclerosis Who Have Walking Disability
There is considerable evidence to support the efficacy of moderate intensity continuous (MIC) exercise benefitting clinically-relevant outcomes in persons with multiple sclerosis (MS).
- Trial name
- NCT04416243
- Testing
- Recumbent Stepping, High-Intensity Interval Training
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Texas, Denton, TX
Multiple Sclerosis, Relapsing Multiple Sclerosis
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
- Trial name
- EXCHANGE (NCT03623243)
- Testing
- Siponimod
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Medical Device
Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP)
The goal of this case control study is to evaluate the use of inertial navigation systems to detect and characterize early locomotor disorders in patients with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Medical Device, Coordination and Balance Disturbances
- Trial name
- IMUSEP (NCT06634225)
- Testing
- Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test
- Where
- 2 sites in France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Lille Catholic University
Multiple Sclerosis
My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis
My MS Toolkit is a web-based symptom self-management program for persons with multiple sclerosis. This study is evaluating various aspects of My MS Toolkit and how it impacts symptom self-management in multiple sclerosis.
- Trial name
- NCT03708276
- Testing
- My MS Toolkit
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.
- Trial name
- NCT06557174
- Testing
- IMC-002, mycophenolate mofetil， MMF
- Volunteers
- 116 people
- Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course.
- Trial name
- O'HAND (NCT04035005)
- Testing
- Ocrelizumab
- Where
- 155 sites in United States, Australia and 21 more
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Insomnia Chronic, Multiple Sclerosis
Mindfulness Meditation in Treating Insomnia in Multiple Sclerosis
Purpose To determine whether Mindfulness-Based Treatment for Insomnia (MBTI) is more effective in the treatment of chronic insomnia disorder (CID) in patients with multiple sclerosis (MS) when compared with standard sleep hygiene…
- Trial name
- NCT03949296
- Testing
- Mindfulness Intervention, Sleep Hygiene
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Griffin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.